Mitopure (Urolithin A)

Name: Timeline Mitopure (Urolithin A)
Brand: Timeline
Price: 65.00 USD
Availability: InStock

Mitopure is a patented form of urolithin A, a postbiotic compound that activates mitophagy (the recycling of damaged mitochondria). Timeline is a Swiss biotech spin-off from EPFL with legitimate research credentials. The science is emerging but intriguing — urolithin A is one of the more novel approaches in the longevity space.

67/ 100

Biorank Score

Independently ranked

67/ 100

Biorank Score

Independently ranked by Biorank Laboratories

Our Verdict

Solid Choice

Timeline Mitopure scores 67 as one of the more novel and scientifically credible entries in the longevity supplement space. The EPFL research pedigree is legitimate, and the published human data (Andreux 2019, Singh 2022) shows measurable outcomes (muscle endurance) rather than just biomarker changes. The score is moderate because the evidence base is still small, the research is largely company-funded, and at $2.17/serving it is expensive for a supplement with limited long-term data.

Key Findings

Urolithin A activates mitophagy — recycling of damaged mitochondria — a well-characterized mechanism
Andreux et al. (2019, Nature Metabolism) showed upregulated mitophagy genes in elderly muscle
Singh et al. (2022, JAMA Network Open) demonstrated ~12% improvement in muscle endurance
Swiss biotech with EPFL research pedigree — more credible than typical supplement startups
Most people cannot produce urolithin A from diet, making supplementation the only reliable source

Evidence Analysis

Urolithin A is a gut-microbiome-derived metabolite of ellagitannins (found in pomegranates). Most people cannot produce sufficient urolithin A from diet because they lack the necessary gut bacteria. Andreux et al. (2019, Nature Metabolism) showed urolithin A upregulated mitophagy gene expression in skeletal muscle of sedentary elderly adults (4-month RCT). Singh et al. (2022, JAMA Network Open) demonstrated that 1000mg urolithin A supplementation improved muscle endurance by ~12% in middle-aged adults. Liu et al. (2022, Cell Reports Medicine) showed improvements in mitochondrial biomarkers. Timeline/Amazentis (the parent company) has funded most of this research, similar to ChromaDex with NR. The mitophagy mechanism is well-characterized in cell and animal models (Ryu et al., 2016, Nature Medicine).

Ingredient Breakdown

Ingredient	Dose	Effective Dose	Adequacy	Verdict
Urolithin A (Mitopure)	500mg	500-1000mg (based on human trials)		Adequate

True Cost Analysis

Properly Dosed -- What You Pay Is What You Get

Listed Price

$2.17/serving

$65.10/month at 1 serving/day

True Cost Per Effective Dose

$2.17/effective dose

$65.10/month for effective dosing

Value Score

Decent value

Save $60.60/month (93%)

by switching to NOW Foods Quercetin 500mg

Where It Falls Short

Most research is funded by Amazentis/Timeline — funder bias is a legitimate concern. At $2.17/serving ($65/month), it is premium-priced for emerging evidence. Long-term safety data beyond 4 months is limited. The muscle endurance improvements (~12%) are modest and may not be noticeable in daily life. Mitophagy is a real biological process but the marketing can oversimplify what 'mitochondrial recycling' means for practical health outcomes. Only two human RCTs published as of 2025.

Best For

Longevity enthusiasts interested in novel mitochondrial health approaches
Sedentary or aging adults concerned about muscle function decline
People who cannot produce urolithin A from diet (most people lack the right gut bacteria)
Those who value supplements from research-backed biotech companies (EPFL spin-off)

Not Ideal For

Budget-conscious consumers (premium pricing for limited human evidence)
Anyone expecting dramatic anti-aging effects (the measured outcomes are modest muscle improvements)
People uncomfortable with most evidence being company-funded
Active, fit individuals who already have healthy mitochondrial function